Thrombolytic efficacy of intravenous recombinant tissue plasminogen activator with different doses

Not Applicable

• Conditions: Diseases of the nervous system

• Registration Number: KCT0000933
• Lead Sponsor: Yonsei University Health System, Severance Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 March 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

? Above 20 year old
? Clear onset time, acute middle cerebral artery infarction patients within 3 hours after onset
? Above 4 of National Institute of Health Stroke Scale
? thin-section noncontrast CT before and after intravenous recombinant tissue plasminogen activator
? patients who treated with intravenous recombinant tissue plasminogen activator
? agreement with this study

Exclusion Criteria

? contraindication of intravenous recombinant tissue plasminogen activator
I.Comatous mentality
II.rapidly improved neurologic deficit or below 4 of National Institute of Health Stroke Scale 4
III.Septic embolism
IV.Risk of bleeding: Known AV malformation of aneurysm, within 7 days of non-compressible site arterial puncture, SAH , INR> 1.7, within 48 hours of heparin and aPTT >1.5 times the upper limit of normal
V.otherwise relative contraindications
? contraindication of CT
? impossible case of thin section brain CT before and after treatment

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
amount of thrombus and change of Hounsfield Unit

Secondary Outcome Measures

Name	Time	Method
recanalization